JP2023547475A5 - - Google Patents

Info

Publication number
JP2023547475A5
JP2023547475A5 JP2023526313A JP2023526313A JP2023547475A5 JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5 JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
alkoxy
alkyl
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547475A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/060043 external-priority patent/WO2022091028A1/en
Publication of JP2023547475A publication Critical patent/JP2023547475A/ja
Publication of JP2023547475A5 publication Critical patent/JP2023547475A5/ja
Pending legal-status Critical Current

Links

JP2023526313A 2020-10-30 2021-10-29 Betブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体2阻害剤の組み合わせを用いて腎機能を改善するための方法 Pending JP2023547475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107853P 2020-10-30 2020-10-30
US63/107,853 2020-10-30
PCT/IB2021/060043 WO2022091028A1 (en) 2020-10-30 2021-10-29 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (2)

Publication Number Publication Date
JP2023547475A JP2023547475A (ja) 2023-11-10
JP2023547475A5 true JP2023547475A5 (cg-RX-API-DMAC7.html) 2024-10-24

Family

ID=81382005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526313A Pending JP2023547475A (ja) 2020-10-30 2021-10-29 Betブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体2阻害剤の組み合わせを用いて腎機能を改善するための方法

Country Status (11)

Country Link
US (1) US12673059B2 (cg-RX-API-DMAC7.html)
EP (1) EP4236955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023547475A (cg-RX-API-DMAC7.html)
KR (1) KR20230098275A (cg-RX-API-DMAC7.html)
CN (1) CN116390721A (cg-RX-API-DMAC7.html)
AU (1) AU2021368618B2 (cg-RX-API-DMAC7.html)
CA (1) CA3197706A1 (cg-RX-API-DMAC7.html)
IL (1) IL301831A (cg-RX-API-DMAC7.html)
MX (1) MX2023004671A (cg-RX-API-DMAC7.html)
TW (1) TW202233194A (cg-RX-API-DMAC7.html)
WO (1) WO2022091028A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112016003584A8 (pt) 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
JP6849804B2 (ja) 2016-12-09 2021-03-31 クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
KR20220124736A (ko) 2020-01-08 2022-09-14 리스버로직스 코퍼레이션 Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법
EP4236957A4 (en) 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Similar Documents

Publication Publication Date Title
US10016426B2 (en) Pharmaceutical compositions for substituted quinazolinones
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP7617898B2 (ja) Eyp001を使用した改善された処置
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
JP2023500685A5 (cg-RX-API-DMAC7.html)
JP2022541503A (ja) Fxrアゴニストを使用した肝疾患の組み合わせ処置
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
JP2006518731A5 (cg-RX-API-DMAC7.html)
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2023526567A5 (cg-RX-API-DMAC7.html)
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
US12478614B2 (en) Inhibitors of glutathione s-transferases (GSTs) and NAD(P)H:quinone oxidoreductase 1 (NQO1), pharmaceutical compositions, and uses in managing cancer
EP3957310B1 (en) Composition comprising sotagliflozin and a tyrosine kinase activity inhibitor for use in the treatment of cancer
CN115397415A (zh) 乳腺癌治疗剂
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
AU2002309211B2 (en) Treatment of renal fibrosis
JP2023509186A5 (cg-RX-API-DMAC7.html)
JP2009506043A5 (cg-RX-API-DMAC7.html)
JP2022502378A5 (cg-RX-API-DMAC7.html)
JP7571024B2 (ja) 抗ccr4抗体抵抗性のがんの治療剤
AU2002309211A1 (en) Treatment of renal fibrosis
CN116390721A (zh) 用于用bet溴结构域抑制剂和钠依赖性葡萄糖转运2抑制剂的组合改善肾功能的方法
JP2023549703A5 (cg-RX-API-DMAC7.html)
JP2021534208A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法